Medicago has developed three proprietary technologies for the development of vaccines: its plant-based Proficia™ technology, Virus-Like Particles (VLPs) and the VLPExpress™ platform. Compared with traditional egg-based and cell production systems, plants are uniquely capable of efficient protein expression at very high yields. Proficia™ is a robust vaccine and antibody production system based on transient protein expression in plant leaves. Medicago’s VLPs mimic the native structure of a virus, allowing them to be recognized readily by the immune system without the core genetic material, making them non-infectious and unable to replicate. VLPExpress™ is a high-throughput platform that accelerates the discovery and development of new vaccines by rapidly expressing, purifying and testing candidate VLPs. The VLPExpress™ platform identifies the best VLP-based antigen presentations for a disease-causing agent within 10 weeks.